23andMe Holding Co. - יחס מחיר להכנסות חזויות ME

23andMe Holding Co. combines retail DNA testing with B2B pharmaceutical partnerships to minimize risk. The forward P/S value on the GURU.Markets chart illustrates the current trend, where the metric is fixed at 0.10. The company generates revenue through subscriptions and the sale of genetic kits, while focusing on drug R&D and the stabilization of its software.

Investing in 23andMe Holding Co. (ME) requires a rigorous filter of fundamental metrics to verify the asset's market value. The business's forward P/S ratio compares current market capitalization with expected sales volumes, allowing for an assessment of the company's valuation adequacy against a systemic decline in demand for genetic tests and a loss of customer trust, which is critical for determining the viability of the issuer's capital.